Return to Listing

11 result(s) for

PI Name Protocol # Title
Jeremy Cetnar IRB00011046 [NCI CIRB]S1400: Lung-MAP, Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Raymond Bergan STUDY00015588 Serial Measurements of Molecular and Architectural Responses to Therapy
Jeremy Cetnar STUDY00015662 CA209-451: A Randomized, Multicenter, Double Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (SCLC) after Completion of Platinum-based First Line Chemotherapy
Jeremy Cetnar STUDY00016230 A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in combination with Ipilimumab placebo Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Christopher Ryan STUDY00017027 A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Renal Cell Carcinoma (FRACTION-RCC)
Jeremy Cetnar STUDY00017685 CA209-816 - Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC
Christopher Ryan STUDY00018084 [NCI CIRB] S1609, "DART: DUAL ANTI-CTLA-4 AND ANTI-PD-1 BLOCKADE IN RARE TUMORS”
Jacqueline Vuky STUDY00018788 A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Jeremy Cetnar STUDY00019009 A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer
Christopher Ryan STUDY00019991 [NCI CIRB] A031704 - PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Christopher Ryan STUDY00020229 [NCI CIRB] A031702 - A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080